Oligonucleotides Market Outlook 2034: Projected to Reach US$ 13.1 Billion by 2034, Driven by Expanding Applications in Biotechnology and Precision Medicine | TMR
02 déc. 2024 10h08 HE
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc.:, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The global oligonucleotides market (mercado de oligonucleótidos) is poised for significant growth,...
Cell and Gene Therapy Tools and Reagents Market Report 2024 - Driving Medical Advances: Cell and Gene Therapy Tools Market to Hit $16.7 Billion by 2029
29 nov. 2024 04h24 HE
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering.The Cell and Gene Therapy Tools and...
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
27 nov. 2024 07h09 HE
|
Ocugen
MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Hemophilia B Treatment Market Surges with 7.6% CAGR, set to Hit $8.97 Billion by 2034 | Fact.MR Report
25 nov. 2024 07h30 HE
|
FACT.MR
Rockville, MD, Nov. 25, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Hemophilia B treatment market is estimated to reach a...
Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider
22 nov. 2024 09h00 HE
|
SNS Insider pvt ltd
Austin, United States, Nov. 22, 2024 (GLOBE NEWSWIRE) -- According to SNS Insider, The Genome Editing Market, valued at USD 7.99 billion in 2023 and is projected to reach USD 32.72 billion by 2032,...
Cancer Gene Therapy Strategic Business Report 2024: Global Market to Grow by $6.5 Billion by 2030 - Rising Interest in Oncolytic Virus Therapy Generates New Opportunities
22 nov. 2024 08h25 HE
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer Gene...
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
21 nov. 2024 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
20 nov. 2024 07h30 HE
|
Ocugen
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
19 nov. 2024 07h02 HE
|
Ocugen
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
18 nov. 2024 11h00 HE
|
Siren Biotechnology, Inc.
Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA